CGEN (Compugen) Payments of Debt: $0.00 Mil (TTM As of Mar. 2026)


CGEN Compugen Ltd CGEN
60 GF Score
Price $2.28
GF Value $5.13
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Compugen Payments of Debt?

Compugen CGEN +6.79% 60 Payments of Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates CGEN with a GF Score™ of 60/100 and a GF Value™ of $5.13 (Possible Value Trap). The stock has 4 warning signs investors should review.

Compugen's Payments of Debt for the three months ended in Mar. 2026 was $0.00 Mil.

Compugen's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Compugen Payments of Debt Related Terms

Compugen Payments of Debt Historical Data

* Premium members only.

The historical data trend for Compugen's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Compugen Payments of Debt Chart

Compugen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Compugen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CGEN
60GF Score
Compugen Ltd CGEN
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Compugen Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $0.00 Mil mean?
Compugen (CGEN) has a Payments of Debt of $0.00 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Compugen and its competitors.
Is Compugen's Payments of Debt too high?
Compugen's current Payments of Debt is $0.00 Mil. Overall, Compugen has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Compugen's Payments of Debt compare to VRTX and REGN?
Compugen's Payments of Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Compugen and its competitors. Compugen's current Payments of Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compugen stock overvalued right now?
Based on GuruFocus' analysis, Compugen (CGEN) is currently considered Possible Value Trap. The stock's GF Value™ is $5.13, compared to a current price of $2.28 — trading 55.6% below its estimated fair value. The current Payments of Debt is $0.00 Mil. Compugen's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Compugen (CGEN), the current Payments of Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Compugen (CGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Compugen stock appears to be undervalued. The current stock price of $2.28 is trading 55.6% below its estimated GF Value™ of $5.13. GuruFocus considers Compugen to be Possible Value Trap.

Key valuation signals for CGEN:

  • Payments of Debt: $0.00 Mil
  • GF Value™: $5.13 vs. price of $2.28 (55.6% below fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the CGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Compugen Business Description

Other Exchanges CGEN:Israel
Address 26 Harokmim Street, Building D, Azrieli Center, Holon, ISR, 5885849
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
60GF Score

Get the complete analysis for CGEN

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.28
Price
$5.13
GF Value